The EU’s medical device regulation
Medical device manufacturers seeking market access
to the European Union (EU) will soon face major changes
in the EU’s decades-old regulatory framework. The EU’s
Medical Device Regulation (MDR) was officially published
on 5 May 2017 and came into force on 25 May 2017.
The MDR will replace the EU’s current Medical Device
Directive (93/42/EEC) and the EU’s Directive on active
implantable medical devices (90/385/EEC).
Medical Devices registration in Japan , quality system requirements and evaluation and investigation of medical devices in regulated countries ASEAN, China JAPAN and WHO regulations. quality and ethical considerations regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.
The EU’s medical device regulation
Medical device manufacturers seeking market access
to the European Union (EU) will soon face major changes
in the EU’s decades-old regulatory framework. The EU’s
Medical Device Regulation (MDR) was officially published
on 5 May 2017 and came into force on 25 May 2017.
The MDR will replace the EU’s current Medical Device
Directive (93/42/EEC) and the EU’s Directive on active
implantable medical devices (90/385/EEC).
Medical Devices registration in Japan , quality system requirements and evaluation and investigation of medical devices in regulated countries ASEAN, China JAPAN and WHO regulations. quality and ethical considerations regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.
Explanation of ISO standard 13485 (QUALITY MANAGEMENT SYSTEM OF MEDICAL DEVICES) in a clarified way to understand it well in a simplified way through this mode. Your comments are appreciated.
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...Swapnil Fernandes
Covers the following details -
- What is QMS ?
- QMS subparts
- QMS Inspection
- What is a label ?
- What is labelling ?
- Labelling requirements and regulations
- Labelling based on the types of submission
The regulation of medical devices in AustraliaTGA Australia
View this presentation for information on:
* what are medical devices, and how they compare to medicines in terms of regulation
* the process for a device to get to market and how they are classified according to risk
* the essential principles and conformity assessment
* safety and performance of devices.
A guideline on medical devices designed internationally for harmonization.
As the site access is unavailable have managed the data for easy access of the details for the Regulatory affairs aspirants of Masters of Pharmacy
Presentation: Clinical Evidence GuidelinesTGA Australia
This presentation provided an insight into the publication of the clinical evidence guidelines and an overview of clinical evidence requirements for medical devices. It also gave information about the level of clinical evidence required and the reason this level of evidence is required. Finally this presentation covered common errors made with clinical evidence.
TGA presentation: medical devices audit assessmentsTGA Australia
An overview of the medical devices audit assessment process, including explanation about the difference between Level 1 and Level 2 audits and the information sponsors are generally required to provide.
Explanation of ISO standard 13485 (QUALITY MANAGEMENT SYSTEM OF MEDICAL DEVICES) in a clarified way to understand it well in a simplified way through this mode. Your comments are appreciated.
Quality System Requirements 21 CFR Part 820 and Labelling Requirements for Me...Swapnil Fernandes
Covers the following details -
- What is QMS ?
- QMS subparts
- QMS Inspection
- What is a label ?
- What is labelling ?
- Labelling requirements and regulations
- Labelling based on the types of submission
The regulation of medical devices in AustraliaTGA Australia
View this presentation for information on:
* what are medical devices, and how they compare to medicines in terms of regulation
* the process for a device to get to market and how they are classified according to risk
* the essential principles and conformity assessment
* safety and performance of devices.
A guideline on medical devices designed internationally for harmonization.
As the site access is unavailable have managed the data for easy access of the details for the Regulatory affairs aspirants of Masters of Pharmacy
Presentation: Clinical Evidence GuidelinesTGA Australia
This presentation provided an insight into the publication of the clinical evidence guidelines and an overview of clinical evidence requirements for medical devices. It also gave information about the level of clinical evidence required and the reason this level of evidence is required. Finally this presentation covered common errors made with clinical evidence.
TGA presentation: medical devices audit assessmentsTGA Australia
An overview of the medical devices audit assessment process, including explanation about the difference between Level 1 and Level 2 audits and the information sponsors are generally required to provide.
Presentation: Conformity Assessment EvidenceTGA Australia
An introduction to conformity assessment procedures for medical devices, good manufacturing practice (GMP), some of the problems commonly experienced by sponsors and TGA, and helpful hints.
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...TGA Australia
An overview of the TGA's implementation of the recommendations made in the Review of Medicines and Medical Devices Regulation and other reforms for the IVD framework
Thanks to a partnership with Jumpshot, Moz is presenting data about Google's search growth, click distribution, and more via a panel of millions of US web users.
Devices Sponsor Information Day: 3A - Medical Devices - Manufacturer's eviden...TGA Australia
Presentations by TGA and Industry (combined) to help sponsors and manufacturers better understand the regulation of medical devices and in-vitro diagnostic medical devices
Sponsor Information and Training day Session A1 – Medical Devices: Efficient ...TGA Australia
Overview
Definitions
Regulatory framework
Mandatory and non-mandatory audits
Common issues and how to avoid them
One-page attachment to provide additional information with the application
Devices Sponsor Information Day: Session 3B: Medical devices (IVDs) - applica...TGA Australia
These presentation papers are provided on the TGA's website solely for the purpose of indicating or suggesting what TGA representatives spoke about to the various conferences and seminars to which it relates. The papers are not legislative in nature and should not be taken to be statements of any law or policy in any way.
Devices Sponsor Information Day: 4A - Medical Devices - Audit assessmentsTGA Australia
Presentations by TGA and Industry (combined) to help sponsors and manufacturers better understand the regulation of medical devices and in-vitro diagnostic medical devices
The challenges of regulating direct to consumer digital medical devicesTGA Australia
Presentation on digital medical devices, the role of the regulator, challenges in applying the framework to digital devices, international approaches and what is the TGA doing
Presentation: Update from the Medical Devices BranchTGA Australia
Under Recommendation 15 of the Review of Medicines and Medical Review Regulation (MMDR) the Government agreed to greater utilisation of marketing approvals by comparable overseas regulators to support assessments of medical devices in Australia. Legislative amendments in the Therapeutic Goods Amendment (2017 Measures No. 1) Act 2018 to enact this change also included clarifications regarding preliminary assessment of applications for pre-market authorisation. This presentation will review the implementation arrangements for these changes, covering the increased options for use of overseas approvals, and the evidence requirements to support applications.
Devices Sponsor Information Day: 0 - Developments in medical device regulationTGA Australia
Presentations by TGA and Industry (combined) to help sponsors and manufacturers better understand the regulation of medical devices and in-vitro diagnostic medical devices
In the USA, medical devices are regulated by the Food and Drug Administration (FDA) with an aim to ensure safety and effectiveness of the devices. The Center for Devices and Radiological Health (CDRH) is an FDA component and looks after this program.
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
Presentation on Pharmacovigilance basics – sponsor obligations, Complementary medicine safety – Regulatory perspective and Special considerations for complementary medicine pharmacovigilance
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
Presentation on using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program (PVIP) update, International collaboration activities, Adverse Event Management System (AEMS)
Q and A
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
Presentation on Legislative requirements, specific risks for IMP manufacturing, manufacturing authorisations, PIC/S Guide to GMP PE009-13 and common issues
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
Presentation on the regulation of software including software as a medical device, proposed regulatory scheme for personalised medical devices, including 3D Printed Devices, proposed changes to the Essential Principles, Conformity Assessment Procedures, and the requirements for devices used in clinical trials, and clarifying the requirements for systems and procedure packs
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
TGA Presentation: Medical Devices - Manufacturer Evidence and applications for inclusion in the ARTG
1. Manufacturer Evidence and applications for
inclusion in the ARTG
Medical Devices
Susan Barker
Devices Application and Verification Section
Medical Devices Branch
Devices Sponsor Information Day
11 October 2017
3. Overview
• Key definitions and regulatory framework
• Manufacturer’s Evidence
• Information in an application
• Avoiding common problems in applications
3
4. What is a medical device?
• Used for human beings
• Intended purpose
– Diagnosis, prevention, monitoring, treatment or alleviation of disease or compensation for injury
or disability
– Investigation, replacement or modification of anatomy or physiological processes
– Control of conception
• Principal intended action
– Not by pharmacological, immunological or metabolic means
• Definition of IVD in the MD Regulations
• Products declared to be or not to be a medical device
– Therapeutic Goods (Articles that are Medical Devices) Specification and/or
Therapeutic Goods (Articles that are not Medical Devices) Orders
• Accessory to a medical device as described above
Therapeutic Goods Act 1989, section 41BD 4
5. What is an IVD?
• A reagent, calibrator, control material, kit, specimen receptacle, instrument,
software, equipment or system
• Intended for the in vitro examination of human specimens for
– giving information about a physiological or pathological state
– giving information about a congenital abnormality
– determining safety and compatibility with a potential recipient
– monitoring therapeutic measures
Therapeutic Goods (Medical Devices) Regulations 2002, Dictionary
5
6. ARTG inclusion
• Any medical device must be included in ARTG
• Except:
- Exempt devices (e.g. custom-made medical devices)
• Sponsor is responsible for ARTG inclusion
• Before you start
• TGA Business Services (TBS)
– Register and get your Client ID
6
8. Manufacturer evidence
• Manufacturer must apply appropriate conformity assessment procedure to the device
(quality management system and control over the design of the device)
• Sponsor must lodge the manufacturer’s certification of the conformity assessment with the
TGA
- Except for Class I medical devices (no measuring function and/or not supplied sterile),
Class 1 IVD, and/or Export Only
• TGA conformity assessment certificate
• EC Certificate issued under MDD 93/42/EEC, AIMDD 90/385/EEC, IVD 98/79/EC
• MRA certificates issued by EU Notified Body (with certain exceptions)
• Declarations of conformity made under Clause 7.5 of Schedule 3 (systems or procedure
packs)
• ISO 13485 for IVDs only 8
10. Application for ARTG inclusion
• Must be made for a kind of device and
• Must be made in accordance with a form and manner approved (via
TBS) and
• Application fee must be paid and
• For the devices that must have TGA conformity assessment certificate
– such certificate is in force and
• Must not contain information that is false or misleading in a material
particular
Therapeutic Goods Act 1989, sections 41FC and 41EA, and Therapeutic Goods (Medical Devices) Regulations 2002, regulation 4.1
10
11. What we look at
Kind of device
Intended Purpose
GMDN Code
Device Product Characteristics
Classification
Conformity Assessment Procedures
11
12. Kind of device
• Sponsor
• Manufacturer
• Device nomenclature system code (GMDN)
• Classification
• Unique product identifier (UPI)
(for Class III and active implantable medical devices (AIMD), and
Class 4IVD, except immunohaematology reagent)
a medical device is taken to
be of the same kind as
another medical device if
they have the same:
Therapeutic Goods Act 1989, section 41BE and Therapeutic Goods (Medical
Devices) Regulations 2002, regulations 1.6 and 1.7 12
13. Intended purpose of a kind of device
• Means the purpose for which the manufacturer of the device intends
it to be used, as stated in the information provided with the device
(labelling, instructions for use, advertising material and technical
documentation)
• Intended purpose stated in the application must be consistent with
the purpose for which the manufacturer intends the devices of the kind
to be used
Note: The manufacturer must have evidence that the device
performs as intended (refer essential principles)
13
14. Global Medical Device Nomenclature (GMDN)
- One of the characteristics that defines the kind of device
- Is to be consistent with the intended purpose of the device
- Must be the code that best describes the kind of device
- For medical devices (not-IVD) – relevant preferred term (except Class
I – relevant template term)
- For IVDs - collective terms (Level 1, 2 or 3) (except
Class 4IVD that is not immunohaematology reagent - relevant
preferred term)
Manufacturer’s responsibility 14
16. Medical devices are classified having regard to
the intended purpose of the device
Class I Class Is and
Class Im
Class IIa Class IIb Class III and
AIMD
The lowest level The highest level
Therapeutic Goods (Medical Devices) Regulations 2002, Part 3
Division 3.1 and Schedules 2 16
17. IVD medical devices are classified having regard to the
intended purpose of the device and its risk to public health
and/or personal risk
• Class 1 IVD – no public health risk or low personal risk
• Class 2 IVD – low public health risk or moderate personal risk
• Class 3 IVD – moderate public health risk or high personal risk
• Class 4 IVD – high public health risk
RISK
Therapeutic Goods (Medical Devices) Regulations 2002, Schedules 2A
17
18. Conformity assessment procedure
• Minimum conformity assessment procedures for different Classes
of devices
• Sufficient information to demonstrate application of the appropriate
conformity assessment procedures to the kind of device
Part 3 Division 3.2 and Schedule 3, Therapeutic Goods (Medical Devices) Regulations 2002
18
19. Conformity assessment procedures
• Minimum conformity assessment procedures for different Classes of
devices
Class Is device
(e.g. Sterile surgical gown)
Class III device
supplied sterile
(e.g. Knee Femur)
Annex II.3 - Full Quality Assurance
Annex V – Production Quality
Plus
Declaration of conformity
(Part 6, Schedule 3)
Annex III - Type Examination
Plus:
Annex V - Production Quality Assurance
Annex II.3 - Full Quality Assurance
Plus
Annex II.4 - Examination of Design
OR
OR
19
20. One page document
• Describe the device and intended purpose if needed in more detail
• Cite the classification rules in accordance with
Schedule 2 or 2A of the Regulations and provide justification where
required
• Explain how the kind of device is covered under the scope of certificate
included in Manufacturer’s Evidence
• Make sure all the information is complete and correct
• Do not attach more than one page
20
21. Information provided in the application
• Do not attach information that is not relevant with the
application, for example:
– Declaration of conformity made under EU Medical Device
Directive
– Audit and/or technical data reports
• Ensure intended purpose is clear and correct
• Ensure the device is classified correctly
• Ensure the Manufacturer’s Evidence stated in the application
contains correct certificate
21
22. Examples of common mistakes
Incorrect Device
Product Characteristics
GMDN code not most
relevant for the kind of
device
Incorrect Classification
Scope of EC certificate
does not correctly cover
the kind of device
Attaching documents not
relevant, which do not
meet requirements
22
23. Where do we go from here?
Matters certified under s.41FD
Ensure all information provided is correct
Any application may be selected for audit
Some applications must be selected for audit
23
28. Juliana William
Sr RA Associate
Baxter Healthcare
11/10/2017 Devices Sponsor Information Day 28
29. Agenda
Successful and Efficient Submission
Preparation
Checks to do
Additional information
Non-mandatory audit submissions
This presentation will not cover details of:
• Systems and Procedure Packs
• Conformity Assessment
• Audit Assessment
• Class III/AIMD, UPI and Variants
• Clinical Evidence & Risk Assessment compliance
11/10/2017 Devices Sponsor Information Day 29
30. Common Deficiencies
Manufacturer Evidence
(ME)
• Two or more
certificates are
provided
• EU declaration of
Conformity
• ISO 13485 certificate
• Incomplete certificate
(missing attachments)
• Incorrect annex route
• Incorrect directive
• Not in English!
Device Application
(DA)
• GMDN code does no
match the ‘Intended
purpose’
• Wrong classification
• Device is not covered in
the EC Certificate scope
• Route of conformity (EC
Certificate Annex) is not
appropriate for the
proposed Class
• Wrong manufacturer
evidence!
Administrative
• Missing documents or
pages!
• TGA evaluator unable to
find information easily
• Poor hyperlinking and
bookmarking
• Spelling errors
• Poor English Translation
• Missing signatures!
• Application fees not
processed
11/10/2017 Devices Sponsor Information Day 30
31. Preparation
Ensure a legal/quality/distribution agreement is/are in place which outline
clearly roles and responsibilities for post-market monitoring, vigilance and
reporting obligations
Obtain Australian Declaration of Conformity from manufacturer
Make sure you have the right template for class and conformity route. See
http://www.tga.gov.au/industry/devices-forms-declaration-conformity.htm
Ensure the codes listed are the code to be registered and marketed
Obtain Australian Essential Principles Checklist from manufacturer
● Ensure compliance with all standards applied and compliance with the Australian EP. Section 8 of the ARGMD
explain the differences between EU ER and Australia EP.
Product Labelling and Instruction for Use
Risk Management Report and Clinical Evaluation Report
11/10/2017 Devices Sponsor Information Day 31
32. Checks to Do
Check whether the device:
Sterile? What is the sterilisation method
Measuring function?
Invasive?
Reusable or Single Use?
Active?
Single product or System or Procedure pack?
Contains a medicine?
Contains material or ingredients of microbial/ recombinant / GMO/ animal/ human
origin? Country of origin?
Is the device classified correctly according to the TGA Classification
Rules? (Schedule 2 of The Regulations)
11/10/2017 Devices Sponsor Information Day 32
33. Checks to Do
The medical devices regulatory
framework has a classification system
for medical devices.
The detailed legislation is in:
• 41BD of the Therapeutic Goods Act
1989 (the Act)
• Regulation 3.2 of the Therapeutic
Goods (Medical Devices)
Regulations 2002 (the Regulations)
• Schedule 2 of the Regulations.
11/10/2017 Devices Sponsor Information Day 33
34. Checks to Do
• Is the assigned GMDN code appropriate? (Section 10 of the Regulation)
Remember that manufacturer assign the GMDN code.
Check if the GMDN is on the TGA database. If the GMDN code is not in the TGA database,
ask for it to be added in advance by email to ebs@tga.gov.au
There may be differences between the GMDN Agency code table database and the TGA code
table database.
Based on the Device information, is the GMDN appropriate and reflects the intended
purpose?
Must be a preferred term
Does the device perform according to its intended purpose?
This should be a detailed description of the manufacturers intended purpose and should closely
align with the relevant GMDN description
Remember: Intended purpose is different from Functional description (describes the
operation of the medical device, not its composition)
11/10/2017 Devices Sponsor Information Day 34
35. Checks to Do
● Is the device same kind of medical device (Section 41BE of The Act)?
A medical device is of the same ‘kind’ if it has the same:
Intended purpose
Classification
GMDN code
Legal manufacturer
Sponsor
Does it have appropriate evidence of Conformity Assessment?
ARGMD Section 5 Conformity Assessment Overview
Need to check the appropriate level and route is held by the manufacturer
according to the classification
11/10/2017 Devices Sponsor Information Day 35
37. Checks to Do
There are a number of
important details that a
sponsor should check to
ensure that the certificate
is valid for particular
devices.
Refer to Section 7 of the
ARGMD
11/10/2017 Devices Sponsor Information Day 37
38. Additional Information
If there is additional information that could help the assessor, then it would
be beneficial to attach a ONE PAGE ONLY document with the application
illustrating:
A Picture/diagram of the device
A description of the device (not the intended purpose)
A description of the mechanism of action (how it works)
How the device is included in the scope of the CE Certificate
Evidence of the same kind of medical device (for multiple devices)
11/10/2017 Devices Sponsor Information Day 38
39. Non-mandatory audit
Any Device Application is subject to non-mandatory audit.
Be prepared to submit any documents from Level 1 or 2 audit list, as well as anything else you may
need to show compliance with any of the Essential Principles or Conformity Assessment
Procedures.
Examples:
Compliance with Essential Principles
Notified Body audit reports to verify the validity of the EC Certificate
Product labelling and IFU
Explanation and justification of Classification
Recent Clinical Evaluation Report
Recent Risk Management File
Compliance with particular standards (or justification why it is not complied with)
Remember you declare you can submit in 20 days!
11/10/2017 Devices Sponsor Information Day 39
40. Non-mandatory audit
Provides all items requested by the TGA
Electronic and easy to navigate (entire document):
Clear table of content (hyperlinking and bookmarking work!)
Text readable
Page numbers throughout
Up-to-date Clinical Evidence Report (signed by a clinical expert!)
Up-to-date Risk Management File
Well prepared submission will:
Allow the delegate to easily navigate and find information quickly.
Reduce the number of questions raised by the delegate
Speed approval
The better quality the submission, the easier it is to read and evaluate
11/10/2017 Devices Sponsor Information Day 40
41. Wrap Up
Make sure you understand your product.
Do your preparation and verify information before submission! Time spent before submitting
is well worth it and will increase your success rate
Engage your cross function team (R&D/Quality/Medical/Clinical..etc) well in advance of your
submission plan. Discuss application requirements and TGA’s expectation.
Submit meaningful, helpful and well-set out information. Perform second check before sending
application and electronic files
Clearly explain the scope of your application in the cover letter
Provide comprehensive Table of Content
Ensure all hyperlinks and bookmarks are actually working
Ensure all documents and attachments are provided with the application!
Don’t submit extra documents that aren’t useful or haven’t been requested
11/10/2017 Devices Sponsor Information Day 41
42. References
The Act
Therapeutic Goods Act 1989
The Regulations
Therapeutic Goods (Medical Device) Regulations 2002
ARGMD
Australian Regulatory Guidance for Medical Devices
11/10/2017 Devices Sponsor Information Day 42